192 related articles for article (PubMed ID: 16439873)
1. Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects.
Thompson M; DeJesus E; Richmond G; Wheeler D; Flaherty J; Piliero P; True A; Chiu YY; Zhang Y; McFalls E; Miralles GD; Patel IH
AIDS; 2006 Feb; 20(3):397-404. PubMed ID: 16439873
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients.
Wright D; Rodriguez A; Godofsky E; Walmsley S; Labriola-Tompkins E; Donatacci L; Shikhman A; Tucker E; Chiu YY; Chung J; Rowell L; Demasi R; Graham N; Salgo M
HIV Clin Trials; 2008; 9(2):73-82. PubMed ID: 18474492
[TBL] [Abstract][Full Text] [Related]
3. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration.
True AL; Chiu YY; Demasi RA; Stout R; Patel I
Pharmacotherapy; 2006 Dec; 26(12):1679-86. PubMed ID: 17125431
[TBL] [Abstract][Full Text] [Related]
5. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.
Ruxrungtham K; Boyd M; Bellibas SE; Zhang X; Dorr A; Kolis S; Kinchelow T; Buss N; Patel IH
J Clin Pharmacol; 2004 Jul; 44(7):793-803. PubMed ID: 15199084
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy.
Bellibas SE; Siddique Z; Dorr A; Bertasso A; Sista P; Kolis SJ; Cotler S; Delora P;
Pediatr Infect Dis J; 2004 Dec; 23(12):1137-41. PubMed ID: 15626952
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients.
Wiznia A; Church J; Emmanuel P; Eppes S; Rowell L; Evans C; Bertasso A;
Pediatr Infect Dis J; 2007 Sep; 26(9):799-805. PubMed ID: 17721374
[TBL] [Abstract][Full Text] [Related]
8. Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide.
Boyd MA; Zhang X; Dorr A; Ruxrungtham K; Kolis S; Nieforth K; Kinchelow T; Buss N; Patel IH
J Clin Pharmacol; 2003 Dec; 43(12):1382-91. PubMed ID: 14615475
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.
Wheeler DA; Lalezari JP; Kilby JM; Wheat J; Delehanty J; DeMasi R; Patel I; Salgo M
J Clin Virol; 2004 Jun; 30(2):183-90. PubMed ID: 15125875
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study.
Panettieri RA; MacIntyre N; Sims M; Kerwin E; Fogarty C; Noonan M; Claus R; Andrews WT
Clin Ther; 2009 Aug; 31(8):1716-23. PubMed ID: 19808130
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.
Elger C; Bialer M; Falcão A; Vaz-da-Silva M; Nunes T; Almeida L; Soares-da-Silva P
Epilepsia; 2013 Aug; 54(8):1453-61. PubMed ID: 23758485
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients.
Mould DR; Zhang X; Nieforth K; Salgo M; Buss N; Patel IH
Clin Pharmacol Ther; 2005 Jun; 77(6):515-28. PubMed ID: 15961983
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
[TBL] [Abstract][Full Text] [Related]
14. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients.
Lalezari JP; Patel IH; Zhang X; Dorr A; Hawker N; Siddique Z; Kolis SJ; Kinchelow T
J Clin Virol; 2003 Oct; 28(2):217-22. PubMed ID: 12957192
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects.
Macha S; Brand T; Meinicke T; Link J; Broedl UC
Clin Ther; 2015 Aug; 37(8):1789-96. PubMed ID: 26138865
[TBL] [Abstract][Full Text] [Related]
16. Postmarketing use of enfuvirtide in veterans: provider compliance with criteria for use, overall efficacy, and tolerability.
Belperio PS; Mole LA; Halloran J; Boothroyd DB; Thomas IC; Backus LI
Ann Pharmacother; 2008 Nov; 42(11):1573-80. PubMed ID: 18940919
[TBL] [Abstract][Full Text] [Related]
17. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.
Santos JR; Llibre JM; Ferrer E; Domingo P; Imaz A; Moltó J; Martin-Iguacel R; Caum C; Podzamczer D; Clotet B
HIV Clin Trials; 2009; 10(6):432-8. PubMed ID: 20133273
[TBL] [Abstract][Full Text] [Related]
19. Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function.
Tebas P; Bellos N; Lucasti C; Richmond G; Godofsky E; Patel I; Chiu YY; Evans C; Rowell L; Salgo M
J Acquir Immune Defic Syndr; 2008 Mar; 47(3):342-5. PubMed ID: 18091608
[TBL] [Abstract][Full Text] [Related]
20. Interaction between enfuvirtide, an injectable fusion inhibitor, and niacin in an HIV-infected patient.
Oates E; Dzintars K
Ann Pharmacother; 2010 Dec; 44(12):2014-7. PubMed ID: 21045170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
